Article Text

other Versions

Download PDFPDF
Randomised, prospective clinical trial of platelet-rich plasma injection in the management of severe dry eye
  1. Marcel Y Avila,
  2. Angela M Igua,
  3. Amparo M Mora
  1. Department of Ophthalmology, Facultad de Medicina, Universidad Nacional de Colombia, Bogota, Colombia
  1. Correspondence to Dr Marcel Y Avila, Department of Ophthalmology, Facultad de Medicina, Universidad Nacional de Colombia, Bogota, DC, Colombia; myavilac{at}


Background To evaluate the effectiveness of platelet-rich plasma (PRP) injections in the treatment of severe dry eye.

Methods This prospective, intervention study included patients with severe dry eye who had been diagnosed with Sjogren syndrome. Patients were divided into two groups. The intervention group received PRP (n=15) injections on days 0, 30, 60 and 90, as well as hyaluronic acid five times per day. The comparison group received hyaluronic acid (n=15) five times per day. Subjects were measured at baseline and at 30, 60 and 90 days. The primary outcome measures were changes in corneal staining according to the Oxford classification, results of the Schirmer test and tear break-up time (TBUT). The secondary outcome measures were changes in the Ocular Surface Disease Index (OSDI) and treatment compliance.

Results All subjects completed the study. The intervention group showed improvements in all primary outcome measures when compared with the control group, including a reduction in corneal staining (p<0.001), increase in the mean Schirmer value from 5.6±0.7 to 9.0±1.1 mm, and an increase in TBUT from 4.0±0.4 to 6.4±0.4 s at day 90. An improvement in subjective OSDI values was also found.

Conclusion PRP injection is safe and effective in improving tear parameters as well as subjective parameters, and was found to be superior to hyaluronic acid alone in the management of patients with severe dry eye. This represent a novel alternative treatment for severe dry eye.

Trial registration number NCT02257957.

  • Sjogren syndrome
  • Platelet Rich Plasma
  • Dry eye
  • Lacrimal gland regeneration.

Statistics from


  • Contributors Contribution of each author is listed as the following. MYA, AMM, AMI: substantial contribution to the conception or design of the work, or the acquisition, analysis or interpretation of data. MYA, AMA: drafting the work or revising it critically for important intellectual content. MYA, AMM, AMI: final approval of the version published. MYA, AMM, AMI: agreement to be accountable for all aspects of the work in ensuring that questions related to the acuity or integrity of any part of the work are appropriately investigated and resolved. 

  • Funding This research was funded by Facultad de Medicina Convocatoria de trabajos de grado 2016.

  • Competing interests None declared.

  • Patient consent Obtained.

  • Ethics approval The protocol was approved by Comite de Etica Facultad de Medicina Universidad Nacional de Colombia.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • At a glance
    Keith Barton James Chodosh Jost B Jonas